MA55872A - Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires - Google Patents

Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires

Info

Publication number
MA55872A
MA55872A MA055872A MA55872A MA55872A MA 55872 A MA55872 A MA 55872A MA 055872 A MA055872 A MA 055872A MA 55872 A MA55872 A MA 55872A MA 55872 A MA55872 A MA 55872A
Authority
MA
Morocco
Prior art keywords
treatment
ocular diseases
sema3a antibodies
sema3a
antibodies
Prior art date
Application number
MA055872A
Other languages
English (en)
Inventor
Rachel Rebecca Barrett
Kristin Laura Bovat
Rajkumar Ganesan
Priyanka Gupta
Fei Han
Dongmei Liu
Juergen Prestle
Sanjaya Singh
Leo Thomas
Sathyadevi Venkataramani
Helen Haixia Wu
Nina Zippel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA55872A publication Critical patent/MA55872A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA055872A 2019-05-09 2020-05-08 Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires MA55872A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09

Publications (1)

Publication Number Publication Date
MA55872A true MA55872A (fr) 2022-03-16

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055872A MA55872A (fr) 2019-05-09 2020-05-08 Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires

Country Status (27)

Country Link
US (3) US11267880B2 (fr)
EP (1) EP3966239A1 (fr)
JP (2) JP7314310B2 (fr)
KR (1) KR20220007128A (fr)
CN (1) CN113795509A (fr)
AR (1) AR122266A1 (fr)
AU (1) AU2020267874A1 (fr)
BR (1) BR112021019854A2 (fr)
CA (1) CA3137377A1 (fr)
CL (1) CL2021002795A1 (fr)
CO (1) CO2021014768A2 (fr)
CR (1) CR20210559A (fr)
DO (1) DOP2021000226A (fr)
EA (1) EA202193038A1 (fr)
EC (1) ECSP21082527A (fr)
IL (1) IL287758A (fr)
JO (1) JOP20210300A1 (fr)
MA (1) MA55872A (fr)
MX (1) MX2021013671A (fr)
MY (1) MY206253A (fr)
PE (1) PE20220287A1 (fr)
PH (1) PH12021552776A1 (fr)
SA (1) SA521430793B1 (fr)
SG (1) SG11202110842QA (fr)
TW (1) TWI836069B (fr)
UA (1) UA129953C2 (fr)
WO (1) WO2020225400A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225400A1 (fr) * 2019-05-09 2020-11-12 Boehringer Ingelheim International Gmbh Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
CN117396504A (zh) 2021-03-30 2024-01-12 拜耳公司 抗Sema3A抗体及其用途
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US20120322085A1 (en) * 2009-11-05 2012-12-20 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
WO2013005603A1 (fr) 2011-07-01 2013-01-10 公立大学法人横浜市立大学 Agent pour la prévention et/ou le traitement d'une inflammation allergique de la conjonctive
JP6372040B2 (ja) 2013-02-06 2018-08-15 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
JP6437462B2 (ja) * 2013-02-21 2018-12-12 アールエスイーエム・リミテッド・パートナーシップ 眼内透過性亢進の予防及び治療におけるｓｅｍａ３ａの阻害
RS61703B1 (sr) * 2014-09-05 2021-05-31 Rsem Limited Partnership Kompozicije i postupci za lečenje i prevenciju zapaljenja
AU2016346595B2 (en) 2015-10-27 2019-11-14 Pangen Biotech Inc. Antibody to be cross-linked to human and mouse Sema3A, and use thereof
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
KR101854529B1 (ko) * 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
WO2020225400A1 (fr) 2019-05-09 2020-11-12 Boehringer Ingelheim International Gmbh Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires

Also Published As

Publication number Publication date
JP2022531698A (ja) 2022-07-08
CA3137377A1 (fr) 2020-11-12
US20200385446A1 (en) 2020-12-10
CL2021002795A1 (es) 2022-08-05
NZ780763A (en) 2025-09-26
US20240336674A1 (en) 2024-10-10
UA129953C2 (uk) 2025-09-24
ECSP21082527A (es) 2021-12-30
JP7638332B2 (ja) 2025-03-03
KR20220007128A (ko) 2022-01-18
PH12021552776A1 (en) 2022-09-19
JP2023130473A (ja) 2023-09-20
JOP20210300A1 (ar) 2023-01-30
JP7314310B2 (ja) 2023-07-25
SG11202110842QA (en) 2021-10-28
WO2020225400A1 (fr) 2020-11-12
MY206253A (en) 2024-12-05
EA202193038A1 (ru) 2022-03-30
MX2021013671A (es) 2021-12-10
AR122266A1 (es) 2022-08-31
CR20210559A (es) 2021-12-23
IL287758A (en) 2022-01-01
EP3966239A1 (fr) 2022-03-16
US11267880B2 (en) 2022-03-08
TW202108621A (zh) 2021-03-01
CN113795509A (zh) 2021-12-14
BR112021019854A2 (pt) 2022-02-15
DOP2021000226A (fr) 2021-12-15
SA521430793B1 (ar) 2024-03-28
PE20220287A1 (es) 2022-02-25
TWI836069B (zh) 2024-03-21
US20220144929A1 (en) 2022-05-12
CO2021014768A2 (es) 2021-11-19
AU2020267874A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EP3749264C0 (fr) Thérapie au laser pour le traitement et la prévention de maladies oculaires
EP4045037C0 (fr) Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1
EP3612566A4 (fr) Anticorps antagonistes de cd 14 pour le traitement de maladies neurodégénératives
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3829595A4 (fr) Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies
EP3858977A4 (fr) Souche pour la prévention et le traitement de maladies métaboliques et utilisation associée
EP3829569A4 (fr) Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex
MA55325A (fr) Composés pour le traitement de maladies pd-l1
EP3937932A4 (fr) Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses
EP4045036A4 (fr) Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3908374A4 (fr) Compositions et méthodes pour le diagnostic et le traitement de maladies neurodégénératives
EP2968470A4 (fr) Protéines de substance d'inhibition mullerienne (mis) modifiées et leurs utilisations pour le traitement de maladies
EP3645039A4 (fr) Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
MA47442A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3986426A4 (fr) Ciblage de l'intégrine alpha3bêta1 pour le traitement du cancer et d'autres maladies
EP4236944A4 (fr) Composés bicycliques et leurs utilisations pour le traitement de maladies
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
EP3911153A4 (fr) Traitement de maladies impliquant une déficience d'enpp1 ou d'enpp3